
If Genmab's drug tisotumab vedotin is approved in the US in October as expected, the firm will take on its own sales and marketing for the first time.
The Danish biotech company is currently expanding its workforce to prepare for participating in commercial activities with US company Seagen, formerly Seattle Genetics, with which it shares the rights for tisotumab vedotin equally.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app